CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.02 CNY | -2.65% |
|
+1.91% | -17.44% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.86B 258M | Sales 2025 * | 2.12B 293M | Capitalization | 8.49B 1.17B |
|---|---|---|---|---|---|
| Net income 2024 * | 720M 99.54M | Net income 2025 * | 812M 112M | EV / Sales 2024 * | 4.56 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4 x |
| P/E ratio 2024 * |
12
x | P/E ratio 2025 * |
10.6
x | Employees | 672 |
| Yield 2024 * |
2.2% | Yield 2025 * |
2.51% | Free-Float | 63.46% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.65% | ||
| 1 week | +1.91% | ||
| Current month | +1.91% | ||
| 1 month | +7.96% | ||
| 3 months | +5.85% | ||
| 6 months | -14.34% | ||
| Current year | -17.44% |
1 week
62.04
66.73
1 month
54.8966.73
Current year
44.7879.08
1 year
44.7888.21
3 years
44.78222.19
5 years
37.53442.67
10 years
37.53442.67
| Managers | Title | Age | Since |
|---|---|---|---|
Qing Han Wang
CEO | Chief Executive Officer | 50 | 17-04-30 |
Wen Nian Wu
DFI | Director of Finance/CFO | 41 | 10-05-31 |
Wen Li Hou
BRD | Director/Board Member | 41 | 17-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Bo Fang
BRD | Director/Board Member | 50 | 20-02-29 |
Zhen Tao Wang
CHM | Chairman | 59 | - |
Xiong Ping Yu
BRD | Director/Board Member | 48 | 17-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 12 M€ | -16.71% | - | |
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 64.02 | -2.65% | 2,133,850 |
| 24-05-09 | 65.76 | +4.88% | 2,981,604 |
| 24-05-08 | 62.7 | -5.09% | 3,169,200 |
| 24-05-07 | 66.06 | -0.02% | 2,237,050 |
End-of-day quote Shenzhen S.E., May 09, 2024
More quotes
Chengdu Kanghua Biological Products Co Ltd is a China-based company principally involved in the research and development, manufacturing and sales of vaccine products. The Company's main products are Rabies Vaccine (human diploid cell) for Human Use, Freeze-dried and Group ACYW135 Meningococcal Polysaccharide Vaccine. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
64.02
CNY
Average target price
94.12
CNY
Spread / Average Target
+47.02%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.44% | 1.17B | |
| -2.35% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- 300841 Stock